7SILVERMAN L R,DEMAKOS E P,PETERSON B L.Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome:a study of the Cancer and Leukemia Group B[J].Clin Oncol,2002,20:2429-2440.
8ISSA J P,GARCIA-MANERO G,GILES F J.Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies[J].Blood,2004,103:1635-1640.
9ZAGONEL V,LO R G,MAROTTA G.5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes[J].Leukemia,1993,7 Suppl 1:30-35.
10KANTARJIAN H,ISSA J P,ROSENFELD C S.Decitabine improves patient outcomes in myelodysplastic syndromes:results of a phase III randomized study[J].Cancer,2006,106:1650-1652,1794-1803.
1Zhang L, Feng Y, Zhang X, et al. Clinical Effect of Cyelosporin A Combined with CAG Regimen on Acute Myelocytic Leukemia Trans- formed from Myelodysplastic Syndrome [J]. Journal of Shanxi Datong University ( Natural Science Edition), 2013, (12) 1 : 23.
2Zhu HH, Jiang H, Jiang B, et al. Cytarabine, aclarubicin and granu- locyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refracto- ry to first course of induction chemotherapy [ J ]. Leukemia & lympho- ma, 2013, 54(11): 2452-2457.
